Core Viewpoint - The company is advancing its internationalization strategy by signing an exclusive supply agreement with GOODFELLOW in the Philippines for the product Efparepoetin alfa, aimed at enhancing economic benefits and brand influence [1][2] Group 1: Strategic Initiatives - The agreement allows the subsidiary Luzhou Bichang Biopharmaceutical Co., Ltd. to appoint GOODFELLOW as the exclusive agent for the registration, clinical trials, promotion, distribution, and sales of Efparepoetin alfa in the target region [1] - This transaction marks a significant breakthrough in the company's internationalization process within its biopharmaceutical strategy, contributing to both economic gains and brand value enhancement [2] Group 2: Market Expansion - The signing of the agreement aims to quickly convert the company's research and development achievements into commercial benefits through collaboration and licensing, thereby broadening the overseas market for Efparepoetin alfa [2] - The company emphasizes a dual approach of independent research and open collaboration, strengthening international partnerships to maximize product value and enhance core competitiveness [2]